10-Q: Creative Medical Reports Increased Losses Amid Clinical Progress

Creative Medical Technology Holdings, Inc. reported an increased net loss for the nine months ended September 30, 2025, despite significant clinical trial advancements and successful capital raises through warrant exercises.

Summary

• Net loss for the nine months ended September 30, 2025, increased to $4,107,334, compared to $3,639,407 for the same period in 2024.
• Revenue decreased to $3,000 for the nine months ended September 30, 2025, from $8,000 in the prior year period.
• Selling, general and administrative expenses rose by 30% to $2,396,735, primarily due to increased marketing expenses and bonus payouts.
• Research and development expenses decreased by 11% to $1,709,719, mainly due to reduced general research and Type I Diabetes trial expenses, partially offset by increased costs for the AlloStemSpine trial and clinical research fees.
• Cash balance as of September 30, 2025, was $5,375,511, down from $5,940,402 at December 31, 2024.
• The company successfully raised approximately $3.7 million in net proceeds from warrant exercises in March 2025, and an additional $3.8 million in October 2025 (subsequent event).
• Positive initial data from the first cohort of the CELZ-201 ADAPT clinical trial for chronic lower back pain showed no dose-limiting toxicities or serious adverse events, with preliminary efficacy signals.
• Dosing for the second cohort of 10 patients in the CELZ-201 ADAPT trial was completed in Q2 2025.

Sentiment

Score: 6

Explanation: The company shows strong clinical progress and successful capital raises, which are positive indicators for future potential. However, the significant increase in net loss, decreased revenue, and higher cash burn from operations reflect ongoing financial challenges typical of a development-stage biotech, balancing optimism with financial realities.

Positives

• Successful completion of an independent interim safety review by the Data Safety Monitoring Board (DSMB) for the CELZ-201 ADAPT clinical trial, allowing the trial to proceed as planned.
• Promising initial data from the first cohort of the CELZ-201 ADAPT clinical trial, showing an excellent safety profile with no serious adverse events and preliminary efficacy signals in alleviating back pain.
• Completion of dosing for the second cohort of 10 patients in the CELZ-201 ADAPT trial, advancing the clinical program.
• Received Orphan Drug Designation (ODD) from the FDA in March 2024 for the treatment of Brittle Type 1 Diabetes using the ImmCelz (CELZ-100) platform, providing significant development benefits.
• FDA clearance for an expanded access therapy using CELZ-201 for managing abnormal glucose tolerance and preventing Type I Diabetes in high-risk individuals.
• Successful generation of human induced pluripotent stem cells (iPSCs)-derived islet cells that produce human insulin, indicating potential for clinical translation.
• Initiation of a program combining artificial intelligence (AI) with proprietary iPSC to diagnose and treat patients exposed to biological and chemical weapons, enhancing research efficiency and innovation.
• Significant capital raised through warrant exercises: approximately $3.7 million in March 2025 and $3.8 million in October 2025 (subsequent event), bolstering liquidity.

Negatives

• Net loss increased to $4,107,334 for the nine months ended September 30, 2025, compared to $3,639,407 in the prior year.
• Operating loss increased to $4,197,032 for the nine months ended September 30, 2025, from $3,858,127 in the prior year.
• Revenue decreased significantly to $3,000 for the nine months ended September 30, 2025, from $8,000 in the comparable period.
• Cash balance decreased to $5,375,511 as of September 30, 2025, from $5,940,402 at December 31, 2024.
• Working capital decreased to $5,150,188 as of September 30, 2025, from $5,807,659 at December 31, 2024.
• Net cash used in operating activities increased by 17% to $3,918,891, indicating higher cash burn from operations.
• Selling, general and administrative expenses increased by 30% due to higher marketing and bonus payouts.

Risks

• Limited operating history and minimal revenues, making the business sensitive to general economic conditions.
• Dependence on successful development, introduction, and marketing of new products and services in a rapidly changing technology environment.
• Potential for products and services to quickly become obsolete and unmarketable due to rapid technological advances and customer demands.
• Limited marketing and distribution capabilities, requiring substantial additional expenses for an internal sales organization and facing competition from well-funded companies.
• Risk of technical or other difficulties delaying or preventing the development, introduction, or marketing of new products or enhanced versions.
• Inability to adapt new or enhanced products and services to emerging industry standards or achieve favorable market reception.
• Insufficient capital resources to further the development of existing and/or new products.
• Unpredictable impact of global supply chain activities, prolonged global conflicts, or sanctions on results of operations.

Future Outlook

The company anticipates continued development of its ImmCelz, StemSpine, and AlloCelz platforms, with ongoing clinical trials for Type I Diabetes (CELZ-201 CREATE-1) and chronic lower back pain (CELZ-201 ADAPT). Future plans include leveraging AI with iPSC for biological and chemical weapon exposure diagnosis and treatment, and exploring collaborations to accelerate development. The company expects to amortize remaining patent costs through 2034 for various patents.

Management Comments

• "We believe this process endows the immune cells with regenerative properties (or supercharges them) providing them with the ability to treat multiple indications."
• "We estimate that the development of this cell line will save the Company two to three years in research and development time along with associated expenses."
• "We believe these results show that we will be able to substantially reduce production costs, while allowing for the manufacture of the best clinical product for patients with immune disorders, which will enable us to accelerate our clinical applications and encourage potential collaborations with respect to our ImmCelz platform."
• "This trial, protected by issued patents, is a huge milestone for the Company and for patients suffering from this debilitating problem and their need for opioids for pain."
• "We believe this development has the potential for not only clinical translation of the human Islet Cells, but also the stand-alone human insulin which is produced by these cells."
• "The use of AI strengthens the Company's research efficiency, precision, and innovation."
• "Blind preliminary data suggest encouraging therapeutic potential in alleviating back pain and restoring functionality."

Industry Context

Creative Medical Technology Holdings operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on regenerative medicine, stem cell therapies, and immunotherapy. The company's efforts to integrate AI into drug discovery and diagnostics align with broader industry trends towards leveraging advanced technologies to accelerate development and improve precision. Its focus on conditions like Type 1 Diabetes and chronic lower back pain addresses significant unmet medical needs, positioning it within a high-growth segment of the healthcare market. The successful generation of iPSC-derived islet cells and the pursuit of Orphan Drug Designation demonstrate a commitment to innovative, specialized treatments, which is a common strategy for smaller biotech firms to gain market traction.

Comparison to Industry Standards

• ImmCelz (CELZ-100) platform required 75% fewer donor patient cells compared to industry standard, suggesting a potential cost and efficiency advantage.
• The purity of the final ImmCelz (CELZ-100) product was greater than 95% compared to the industry standard of greater than 80%, indicating a higher quality therapeutic product.
• ImmCelz (CELZ-100) demonstrated a greater than 200% reduction in functional suppression of effector T cells, which is a critical concern for patients with autoimmune issues, while still possessing a high number of functional T regulatory cells, suggesting a superior immunological profile compared to typical approaches.

Legal Proceedings

• The company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business, with inherent uncertainties that could harm the business.

Related Party Transactions

• Acquisition of ED Patent from CMH (a related company) in February 2016.
• Acquisition of Lower Back Patent from CMH (a related company) in May 2017, with various milestone payments made to CMH.
• Patent License Agreement with Jadi Cell, LLC (controlled by Dr. Amit Patel, a former director) for ImmCelz, Inc. in December 2020.
• Timothy Warbington, CEO, purchased one share of Series B Preferred Stock on May 14, 2024, which was automatically redeemed on December 9, 2024.

Stakeholder Impact

• **Shareholders**: Dilution risk from warrant exercises, but also potential for value creation through clinical advancements and capital raises. Increased net losses and cash burn could negatively impact share price.
• **Employees**: Continued investment in R&D and marketing, including bonus payouts, suggests ongoing operational activity and potential for growth.
• **Customers (Physicians)**: Continued marketing and sales efforts for CaverStem and FemCelz kits, and potential for new therapeutic options from pipeline development.
• **Patients**: Progress in clinical trials for Type 1 Diabetes and chronic lower back pain offers hope for new treatments, especially with Orphan Drug Designation and expanded access therapy.
• **Creditors**: Capital raises improve liquidity, potentially reducing short-term credit risk, but ongoing losses indicate reliance on external financing.

Next Steps

• Continue patient recruitment and dosing for the Type I Diabetes (CELZ-201 CREATE-1) clinical trial.
• Gather additional comprehensive data from the second and third cohorts of the CELZ-201 ADAPT clinical trial to guide future clinical and regulatory plans.
• Further develop the iPScelz program, including evaluating other collaborators, partners, and business opportunities.
• Continue to amortize remaining patent costs for various intellectual properties through their respective expiration periods (e.g., ED patent through 2026, Lower Back Patent through 2026 and 2034, ImmCelz patent through 2030).
• Obtain stockholder approval for the issuance of shares underlying the Inducement Warrants from the October 25, 2025 transaction.

Key Dates

Recommendation

The company demonstrates significant clinical progress with positive safety and preliminary efficacy data from its trials, alongside successful capital raises that provide necessary liquidity for ongoing operations. The Orphan Drug Designation and AI integration are also strong strategic positives. However, the substantial increase in net losses, declining revenue, and accelerated cash burn indicate that the company remains in a high-risk, development-stage phase with no clear path to profitability in the near term. The stock is speculative, and while there are promising developments, the financial performance warrants a 'hold' rather than a 'buy' until there is clearer evidence of commercialization potential or a reduction in losses.

Keywords

Biotechnology, Stem Cells, Immunotherapy, Regenerative Medicine, Clinical Trials, FDA, Orphan Drug Designation, Type 1 Diabetes, Lower Back Pain, iPSC, AI in Biotech, CELZ, SEC Filing, 10-Q